5 research outputs found
M1010 Improved One-Year Graft Survival in Liver Transplant Recipients Treated With Mychophenolate Mofetil: Results of the Liver-Match Prospective Cohort Study
Personal webmelody: Customized sonification of web servers
Presented at the 7th International Conference on Auditory Display (ICAD), Espoo, Finland, July 29-August 1, 2001.This paper presents Personal WebMelody, a sonified web server that informs its administrator of both normal and abnormal operation through background music. It allows customization and full integration of system-generated music representing web server activity with external music sources (audio CD, MP3, etc) selected by the administrator. Our sonification technique works by associating MIDI or WAV sound tracks with web server events. In an attempt to enable the webmaster to listen to such system-generated music for a long period without becoming fatigued, we introduce the opportunity of mixing an external music source with systemgenerated music. In this way, the administrator can hear the status of the web server while listening to his or her preferred music. We present an empirical study that shows how our web server sonification can convey useful information efficiently
Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation
Abstract
There are reports of pretransplant sofosbuvir (SOF) plus ribavirin being effective in preventing recurrent hepatitis C virus (HCV) infection after liver transplantation (LT). The aim of this study was to assess the cost-effectiveness of this strategy in the area served by the North Italy Transplant program. We retrospectively assessed the impact of HCV infection on post-LT survival in 2376 consecutive adult patients (MELD ≤ 25, unknown genotype, period 2004-2009) and the prevalence costs of conventional standard of care (SOC) antiviral therapy (pegylated interferon plus ribavirin) after LT. A Markov model was developed to compare two strategies: 12-24 weeks of SOF+ ribavirin for pre-LT anti-HCV treatment versus on-demand post-LT SOC antiviral therapy. Among the 1794 patients undergoing LT, 860 (48%) were HCV+ and 50% of them were given SOC therapy after LT (mean cost of drugs and adverse effect management = 14,421€ per patient). HCV etiology had a strong impact on post-LT survival (hazard ratio = 1.59, 95% CI = 1.22-2.09, P = 0.0007). After Monte Carlo simulation, pre-LT SOF therapy showed a median survival benefit of 1.5 quality-adjusted life years and an Incremental cost-effectiveness ratio (ICER) of 30,663€/QALY, proving cost-effective in our particular Italian scenario. The costs of SOF therapy, sustained viral response rate 12 weeks after LT, and recipient's age were the main ICER predictors at multivariate analysis. This study proposes a dynamic model based on real-life data from northern Italy for adjusting the costs of pre-LT direct-acting antiviral therapies to the actual sustained virological response reached after LT.
© 2015 Steunstichting ESOT.
KEYWORDS:
cost-effectiveness analysis; hepatitis C virus infection; liver transplantation; recurrent HCV; sofosbuvi
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching
The Liver Match is an observational cohort study that prospectively enrolled liver transplantations performed at 20 out of 21 Italian Transplant Centres between June 2007 and May 2009. Aim of the study is to investigate the impact of donor/recipient matching on outcomes. In this report we describe the study methodology and provide a cross-sectional description of donor and recipient characteristics and of graft allocation